Apoptosis regulatory pathways in erythroid progenitors

Apoptosis regulatory pathways in erythroid progenitors encompass the molecular signaling networks that control the survival and programmed death of red blood cell precursors. In normal physiology, these pathways ensure the production of a healthy red cell mass, primarily regulated by erythropoietin (EPO) binding to its receptor (EPOR) to suppress apoptosis via JAK2/STAT5 and BCL-xL induction (UniProt: P19235). However, in pathological states such as myelodysplastic syndromes (MDS) and beta-thalassemia, these pathways become dysregulated, leading to ineffective erythropoiesis where progenitors die prematurely in the bone marrow (PubMed: 11133746). Therapeutic strategies target these pathways using erythropoiesis-stimulating agents (ESAs) to boost survival signals or TGF-beta superfamily ligand traps like luspatercept, which inhibit inhibitory SMAD2/3 signaling to allow late-stage erythroid maturation (NEJM: 382:140-151). Monitoring these pathways often involves assessing serum EPO levels or markers of progenitor death like Annexin V (Blood: 10.1182/blood-2002-06-1663). Clinical management of these pathways requires balancing red cell production against risks such as hypertension and thromboembolic events.

Other names

Erythroid apoptosis regulationIneffective erythropoiesis pathwaysProgrammed cell death in erythroid precursors

Modulation of erythroid progenitor survival through Erythropoietin receptor (EPOR) activation or inhibition of pro-apoptotic TGF-beta superfamily signaling.